Significant Improvement in PFS and DOR: LITESPARK-011 Validates Clinical Benefit of a Novel Combination Following Immunotherapy Progression

Significant Improvement in PFS and DOR: LITESPARK-011 Validates Clinical Benefit of a Novel Combination Following Immunotherapy Progression

For patients with advanced renal cell carcinoma (RCC) who have progressed after anti-PD-(L)1 therapy, a consensus standard of care is currently lacking. Belzutifan, a first-in-class HIF-2α inhibitor, combined with the VEGFR-TKI lenvatinib, has emerged as a promising therapeutic strategy. At a recent academic conference, Professor Robert J. Motzer from Memorial Sloan Kettering Cancer Center (MSKCC) presented the latest results from the randomized, open-label, Phase 3 LITESPARK-011 study.
Toward Precision Bladder Preservation: RETAIN 2 Validates Nivolumab Plus NAC Potential; ctDNA Emerges as a Key Systemic Risk Predictor

Toward Precision Bladder Preservation: RETAIN 2 Validates Nivolumab Plus NAC Potential; ctDNA Emerges as a Key Systemic Risk Predictor

At the recent genitourinary oncology symposium, Dr. Pooja Ghatalia from Fox Chase Cancer Center presented the primary clinical outcomes of the RETAIN 2 trial. She also provided an integrated analysis of the RETAIN 1 and RETAIN 2 trials, focusing on the role of circulating tumor DNA (ctDNA) in guiding response-adapted bladder preservation for patients with muscle-invasive bladder cancer (MIBC).
Dual Liquid Biopsy Insights: Combining utDNA and ctDNA to Identify pCR and Inform Bladder-Sparing Strategies in MIBC

Dual Liquid Biopsy Insights: Combining utDNA and ctDNA to Identify pCR and Inform Bladder-Sparing Strategies in MIBC

At the recent ASCO Annual Meeting, Professor Michiel S. van der Heijden from the Netherlands Cancer Institute (NKI) presented the latest biomarker analysis from the Phase III NIAGARA trial. The study investigated the dynamics of urinary tumor DNA (utDNA) and circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) receiving perioperative durvalumab in combination with chemotherapy, evaluating their utility in predicting pathological complete response (pCR) and event-free survival (EFS).
Milestone Breakthrough: KEYNOTE-B15 Study Confirms Perioperative EV plus Pembrolizumab Significantly Improves Outcomes in Cisplatin-Eligible MIBC

Milestone Breakthrough: KEYNOTE-B15 Study Confirms Perioperative EV plus Pembrolizumab Significantly Improves Outcomes in Cisplatin-Eligible MIBC

During a recent clinical oncology symposium, Professor Matthew D. Galsky from the Icahn School of Medicine at Mount Sinai presented the primary results of the Phase 3 KEYNOTE-B15 study (also known as EV-304). This trial evaluated the efficacy and safety of perioperative enfortumab vedotin (EV) in combination with pembrolizumab for patients with cisplatin-eligible muscle-invasive bladder cancer (MIBC).
A Breakthrough in Luminal-Targeted Therapy: First-in-Class PPARG Inhibitor FX-909 Demonstrates Potent Antitumor Activity and Precision Subtyping Potential

A Breakthrough in Luminal-Targeted Therapy: First-in-Class PPARG Inhibitor FX-909 Demonstrates Potent Antitumor Activity and Precision Subtyping Potential

At a recent major international oncology conference, Dr. Matthew D. Galsky from Mount Sinai presented updated data from a Phase 1 clinical trial (Late-Breaking Abstract, LBA639) and associated biomarker analysis of FX-909, a first-in-class peroxisome proliferator-activated receptor gamma (PPARG) inhibitor, in patients with advanced urothelial carcinoma (UC). The study data were simultaneously published in the top-tier journal Nature Medicine.
HCRN GU 20-444 Trial: Phase II Clinical Results of Pembrolizumab Monotherapy with a Response-Guided Bladder-Sparing Strategy in MIBC

HCRN GU 20-444 Trial: Phase II Clinical Results of Pembrolizumab Monotherapy with a Response-Guided Bladder-Sparing Strategy in MIBC

While radical cystectomy (RC) remains the standard of care for muscle-invasive bladder cancer (MIBC), it is associated with significant morbidity and long-term quality-of-life impacts. For elderly patients and those ineligible for cisplatin-based chemotherapy, effective bladder-sparing strategies are urgently needed in clinical practice. At a recent major international oncology conference, Dr. Jonathan F. Anker from Mount Sinai presented the latest data from the HCRN GU 20-444 study (Abstract 737). This Phase II clinical trial innovatively explored a pembrolizumab-based, response-guided bladder-sparing strategy in cisplatin-ineligible MIBC patients and conducted an in-depth analysis of the immense potential of circulating tumor DNA (ctDNA) in precisely identifying the population that stands to benefit. Oncology Frontier has summarized the core academic content below.
43.2% Clinical Benefit Rate: Cabozantinib Demonstrates Potential in Heavily Pretreated R/R GCT

43.2% Clinical Benefit Rate: Cabozantinib Demonstrates Potential in Heavily Pretreated R/R GCT

During a recent oncology symposium, Dr. Jennifer King from Indiana University presented the results of a Phase II clinical trial (Abstract 587) evaluating cabozantinib in patients with relapsed/refractory germ-cell tumors (R/R GCT). This study explores the efficacy and safety of a multi-target tyrosine kinase inhibitor (TKI) in a patient population that has failed multiple lines of standard therapy.
Targeting HIF-2α and CDK4/6: A Novel Combination Strategy for Pretreated

Targeting HIF-2α and CDK4/6: A Novel Combination Strategy for Pretreated

In a recent academic session, Professor David F. McDermott from Beth Israel Deaconess Medical Center presented the latest findings from Part 1 of the LITESPARK-024 study. This trial evaluated the safety and preliminary efficacy of the HIF-2α inhibitor belzutifan in combination with the CDK4/6 inhibitor palbociclib in patients with previously treated advanced clear cell renal cell carcinoma (ccRCC).
Launch of the K-COMPAsS Model: A New Era of Precise Prognostic Assessment for Oligometastatic Clear Cell Renal Cell Carcinoma

Launch of the K-COMPAsS Model: A New Era of Precise Prognostic Assessment for Oligometastatic Clear Cell Renal Cell Carcinoma

At a recent international academic conference, Professor Chad Tang from The University of Texas MD Anderson Cancer Center presented pioneering research on circulating Kidney Injury Molecule-1 (KIM-1) and circulating tumor DNA (ctDNA) as prognostic markers for oligometastatic clear cell renal cell carcinoma (ccRCC). During the session, he officially introduced the K-COMPAsS model.
Setback in First-Line Advanced Urothelial Carcinoma Exploration: Adding Anti-LAG-3/TIGIT to EV + Pembrolizumab Yields No Additional Benefit

Setback in First-Line Advanced Urothelial Carcinoma Exploration: Adding Anti-LAG-3/TIGIT to EV + Pembrolizumab Yields No Additional Benefit

At a recent international oncology academic conference, Professor Avivit Peer presented the latest findings from the KEYMAKER-U04 Substudy 04B. This study investigated the efficacy and safety of adding an anti-LAG-3 or anti-TIGIT antibody to the standard-of-care enfortumab vedotin (EV) plus pembrolizumab backbone as a first-line treatment for advanced urothelial carcinoma (UC). Our editorial team has summarized the core academic content for our readers.